INNOVATE Corp. Announces Second Quarter 2025 Results
INNOVATE Corp. (NYSE:VATE) reported Q2 2025 results with revenue declining 22.7% to $242.0 million from $313.1 million in Q2 2024. The company posted a net loss of $22.0 million ($1.67 per share) compared to net income of $14.1 million ($1.03 per share) in the prior year quarter.
Key segment performance includes: Infrastructure revenue decreased 23.6% to $233.1 million with a strong backlog of $1.3 billion; Life Sciences saw 88.2% revenue growth to $3.2 million with R2's system unit sales up 124.5%; Spectrum revenue declined to $5.7 million from $6.2 million.
The company completed significant refinancing transactions extending debt maturities, including exchange offers, convertible notes negotiations, and credit agreement amendments across multiple subsidiaries.
INNOVATE Corp. (NYSE:VATE) ha riportato i risultati del secondo trimestre 2025 con ricavi in calo del 22,7%, attestandosi a 242,0 milioni di dollari rispetto ai 313,1 milioni di dollari del secondo trimestre 2024. La società ha registrato una perdita netta di 22,0 milioni di dollari (1,67 dollari per azione) rispetto a un utile netto di 14,1 milioni di dollari (1,03 dollari per azione) nello stesso periodo dell'anno precedente.
Le performance chiave per segmento includono: i ricavi del segmento Infrastrutture sono diminuiti del 23,6% a 233,1 milioni di dollari, con un solido portafoglio ordini pari a 1,3 miliardi di dollari; il segmento Scienze della Vita ha registrato una crescita dei ricavi dell'88,2%, raggiungendo 3,2 milioni di dollari, con le vendite delle unità del sistema R2 aumentate del 124,5%; i ricavi del segmento Spectrum sono scesi a 5,7 milioni di dollari dai 6,2 milioni precedenti.
L'azienda ha completato importanti operazioni di rifinanziamento estendendo le scadenze del debito, inclusi scambi di titoli, negoziazioni di note convertibili e modifiche agli accordi di credito in diverse controllate.
INNOVATE Corp. (NYSE:VATE) reportó resultados del segundo trimestre de 2025 con ingresos que disminuyeron un 22,7%, alcanzando 242,0 millones de dólares desde 313,1 millones en el segundo trimestre de 2024. La compañía registró una pérdida neta de 22,0 millones de dólares (1,67 dólares por acción) en comparación con una ganancia neta de 14,1 millones (1,03 dólares por acción) en el mismo periodo del año anterior.
El desempeño clave por segmento incluye: ingresos en Infraestructura que bajaron un 23,6% a 233,1 millones con una sólida cartera de pedidos de 1,3 mil millones; Ciencias de la Vida mostró un crecimiento de ingresos del 88,2% hasta 3,2 millones, con ventas de unidades del sistema R2 incrementadas en un 124,5%; los ingresos de Spectrum disminuyeron a 5,7 millones desde 6,2 millones.
La empresa completó importantes transacciones de refinanciamiento extendiendo los vencimientos de la deuda, incluyendo ofertas de intercambio, negociaciones de notas convertibles y enmiendas a acuerdos de crédito en múltiples subsidiarias.
INNOVATE Corp. (NYSE:VATE)는 2025년 2분기 실적을 발표하며 매출이 2024년 2분기 3억 1,310만 달러에서 22.7% 감소한 2억 4,200만 달러를 기록했습니다. 회사는 2,200만 달러(주당 1.67달러)의 순손실을 기록했으며, 이는 전년 동기 순이익 1,410만 달러(주당 1.03달러)와 대비됩니다.
주요 부문별 실적은 다음과 같습니다: 인프라 매출은 23.6% 감소한 2억 3,310만 달러이며, 13억 달러의 견고한 수주 잔고를 보유하고 있습니다; 생명과학 부문은 88.2% 매출 성장으로 320만 달러를 기록했으며, R2 시스템 단위 판매가 124.5% 증가했습니다; Spectrum 매출은 620만 달러에서 570만 달러로 감소했습니다.
회사는 여러 자회사를 대상으로 한 교환 제안, 전환사채 협상, 신용 계약 수정 등을 포함한 주요 재융자 거래를 완료하여 부채 만기를 연장했습니다.
INNOVATE Corp. (NYSE:VATE) a publié ses résultats du deuxième trimestre 2025, avec un chiffre d'affaires en baisse de 22,7 % à 242,0 millions de dollars contre 313,1 millions de dollars au deuxième trimestre 2024. La société a enregistré une perte nette de 22,0 millions de dollars (1,67 dollar par action) contre un bénéfice net de 14,1 millions de dollars (1,03 dollar par action) au trimestre précédent.
Les performances clés par segment incluent : les revenus de l'Infrastructure ont diminué de 23,6 % pour atteindre 233,1 millions de dollars, avec un carnet de commandes solide de 1,3 milliard de dollars ; les Sciences de la Vie ont connu une croissance des revenus de 88,2 % à 3,2 millions de dollars, avec une augmentation de 124,5 % des ventes unitaires du système R2 ; les revenus de Spectrum ont baissé à 5,7 millions de dollars contre 6,2 millions.
L'entreprise a finalisé d'importantes opérations de refinancement prolongeant les échéances de la dette, incluant des offres d'échange, des négociations sur des obligations convertibles et des amendements aux accords de crédit dans plusieurs filiales.
INNOVATE Corp. (NYSE:VATE) meldete die Ergebnisse für das zweite Quartal 2025 mit einem Umsatzrückgang von 22,7 % auf 242,0 Millionen US-Dollar gegenüber 313,1 Millionen US-Dollar im zweiten Quartal 2024. Das Unternehmen verzeichnete einen Nettoverlust von 22,0 Millionen US-Dollar (1,67 US-Dollar pro Aktie) im Vergleich zu einem Nettogewinn von 14,1 Millionen US-Dollar (1,03 US-Dollar pro Aktie) im Vorjahresquartal.
Die wichtigsten Segmentleistungen umfassen: Der Umsatz im Bereich Infrastruktur sank um 23,6 % auf 233,1 Millionen US-Dollar bei einem starken Auftragsbestand von 1,3 Milliarden US-Dollar; Life Sciences verzeichnete ein Umsatzwachstum von 88,2 % auf 3,2 Millionen US-Dollar, wobei die Verkäufe der R2-Systemeinheiten um 124,5 % zunahmen; der Umsatz im Bereich Spectrum ging von 6,2 Millionen auf 5,7 Millionen US-Dollar zurück.
Das Unternehmen schloss bedeutende Refinanzierungstransaktionen ab, die die Fälligkeiten der Schulden verlängerten, darunter Umtauschangebote, Verhandlungen über Wandelanleihen und Änderungen der Kreditverträge bei mehreren Tochtergesellschaften.
- Infrastructure segment maintains strong backlog of $1.3 billion, up from $1.1 billion in December 2024
- Life Sciences revenue grew 88.2% YoY with R2's system unit sales increasing 124.5%
- Successfully completed comprehensive refinancing transactions extending debt maturities
- MediBeacon received NMPA approval in China for TGFR Monitor and Sensor
- Revenue declined 22.7% year-over-year to $242.0 million
- Net loss of $22.0 million compared to $14.1 million profit in prior year
- Total Adjusted EBITDA decreased 41.2% to $15.7 million
- Infrastructure segment saw 230 basis points gross margin compression
- Spectrum segment experiencing softer ad sales and network churn
Insights
INNOVATE reports substantial revenue decline of 22.7% and swings to $22M loss amid infrastructure segment struggles, despite refinancing achievements.
INNOVATE Corp's Q2 2025 results reveal significant financial deterioration across most key metrics. Revenue declined
The company's Adjusted EBITDA saw a concerning
While management highlighted positives like DBMG's strong backlog (
The refinancing transactions completed on August 4th represent the most positive development, extending debt maturities and potentially improving financial flexibility. These transactions included exchanges of senior secured notes, convertible senior notes, and extensions of various credit agreements and notes.
The Life Sciences segment provided a rare bright spot with
- Infrastructure: Improved financial flexibility with recent refinancing transactions -
- Life Sciences: R2 continuing to see significant year over year growth in system unit sales -
- Spectrum: Launched fourth ATSC 3.0 station in collaboration with large mobile carrier -
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (“INNOVATE” or the “Company”) (NYSE: VATE) announced today its consolidated results for the second quarter.
Financial Summary
| (in millions, except per share amounts) | Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||
| 2025 | 2024 | Increase / (Decrease) | 2025 | 2024 | Increase / (Decrease) | |||||||||||||||
| Revenue | $ | 242.0 | $ | 313.1 | (22.7 | )% | $ | 516.2 | $ | 628.3 | (17.8 | )% | ||||||||
| Net (loss) income attributable to common stockholders and participating preferred stockholders | $ | (22.0 | ) | $ | 14.1 | (256.0 | )% | $ | (46.8 | ) | $ | (3.6 | ) | (1200.0 | )% | |||||
| Basic (loss) earnings per share attributable to common stockholders(1) | $ | (1.67 | ) | $ | 1.11 | (250.5 | )% | $ | (3.56 | ) | $ | (0.35 | ) | (917.1 | )% | |||||
| Diluted (loss) earnings per share attributable to common stockholders(1) | $ | (1.67 | ) | $ | 1.03 | (262.1 | )% | $ | (3.56 | ) | $ | (0.35 | ) | (917.1 | )% | |||||
| Total Adjusted EBITDA(2) | $ | 15.7 | $ | 26.7 | (41.2 | )% | $ | 22.9 | $ | 39.5 | (42.0 | )% | ||||||||
(1) Basic and diluted (loss) earnings per common share for the three months and six months ended June 30, 2024, has been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on August 8, 2024.
(2) Reconciliation of GAAP to Non-GAAP measures follows
Commentary
“INNOVATE continued its strong progress across our operating segments this quarter, particularly in maintaining disciplined execution and pursuing strategic opportunities that support long-term value creation. Our recent refinancing transactions will allow us to focus on executing our strategic plans,” said Avie Glazer, Chairman of INNOVATE. “The Infrastructure segment's adjusted backlog remained strong at
“We continue to execute on our strategic priorities across INNOVATE, with a focus on long-term value creation,” said Paul Voigt, Interim CEO of INNOVATE. “DBM maintained their strong backlog in the second quarter and anticipates continued momentum in the third quarter. R2 continues to drive growth with shipments outside North America and at Spectrum, the team is well-positioned for a stronger second half. We also recently completed refinancing transactions that, among other things, extends our debt maturities.”
Second Quarter 2025 and Recent Highlights
- On August 4, 2025, INNOVATE closed a series of previously announced indebtedness refinancing transactions that, among other things, extend the Company's debt maturities.
- The refinancing transactions include (i) the initial closing of an exchange offer and consent solicitation with respect to the Company’s senior secured notes, (ii) privately negotiated exchanges of certain of the Company's convertible senior notes, (iii) amendment and extension of the Company’s 2020 Revolving Credit Agreement, (iv) amendment and extension of the Company's Continental General Insurance Company (“CGIC”) note, as well as the exchange of a portion of the Company's preferred stock held by CGIC in exchange for increasing the principal amount of that note, (v) amendment and extension of the Spectrum Notes, and (vi) amendment and extension of the R2 Technologies, Inc. (“R2”) note.
Infrastructure
- DBM Global ("DBMG") reported second quarter 2025 revenue of
$233.1 million , a decrease of23.6% , compared to$305.2 million in the prior year quarter. Net income attributable to INNOVATE was$5.5 million , compared to$21.0 million for the prior year quarter. Adjusted EBITDA decreased to$19.3 million from$32.5 million in the prior year quarter. - DBMG reported gross margin of
17.9% in the second quarter, a compression of approximately 230 basis points year-over-year and Adjusted EBITDA margin of8.3% in the second quarter, a compression of approximately 240 basis points year-over-year. - DBMG’s reported backlog and adjusted backlog, which takes into consideration awarded but not yet signed contracts, was
$1.3 billion as of June 30, 2025, compared to reported and adjusted backlog of$1.0 billion and$1.1 billion , respectively, as of December 31, 2024. - As previously announced, DBMG has entered into an amended and restated credit agreement that provides for an
$85 million term loan and a$135 million revolving credit facility (the “Credit Facility”), which was used to fully repay DBMG’s existing debt obligations and provide additional working capital capacity. The Credit Facility will expire May 20, 2030.
Life Sciences
- The National Medical Products Administration (“NMPA”) in China approved the MediBeacon® TGFR Monitor and TGFR Sensor for the assessment of kidney function in patients with normal or impaired renal function. Lumitrace® (relmapirazin) injection, categorized as a drug in China, continues to be under review and is targeted for approval in late 2025.
- R2 reported second quarter 2025 revenue of
$3.2 million , an88.2% increase compared to$1.7 million in the prior year quarter. - R2's gross worldwide system unit sales grew
124.5% in the second quarter of 2025 compared to the prior year quarter. - R2 reached an agreement, to, among other things, extend the maturity of R2 Technologies'
20.0% senior secured promissory note to Lancer Capital to August 1, 2026. The amended R2 Note will have an interest rate of12% and remove certain exit and default fees. All interest and fees (including a5% extension fee) accrued through August 4, 2025, will be added to the principal amount.
Spectrum
- Broadcasting reported second quarter 2025 revenue of
$5.7 million , compared to$6.2 million in the prior year quarter. Net loss attributable to INNOVATE was$6.1 million compared to$5.0 million in the prior year quarter. Adjusted EBITDA was$1.0 million , compared to$1.5 million in the prior year quarter. - After softer ad sales and network churn in the first half, Spectrum is now seeing a number of new network launches along with projected improvement in fourth quarter ad sales.
- New datacasting initiatives with ATSC 3.0 promise to soon generate revenues. Spectrum's launch of three ATSC 3.0 stations for a large mobile carrier will be exploring new datacasting commercial opportunities.
- Reached an agreement with the note holders of Spectrum’s
8.50% and11.45% Notes to, among other things, extend the maturity of such notes to September 30, 2026.
Second Quarter 2025 Financial Highlights
- Revenue: For the second quarter of 2025, INNOVATE's consolidated revenue was
$242.0 million , a decrease of22.7% , compared to$313.1 million for the prior year quarter. The decrease was primarily driven by our Infrastructure segment and to a lesser extent by our Spectrum segment, which was partially offset by an increase at our Life Sciences segment. The decrease at our Infrastructure segment was primarily driven by the timing and size of projects at Banker Steel, DBMG's commercial structural steel fabrication and erection business, the industrial maintenance and repair business and the construction modeling and detailing business, including the effect of changes in estimated costs to complete those projects recognized in the ordinary course of business in the comparable period, which also had increased activity in the comparable period on certain large commercial construction projects that have since been completed or are nearing completion in the current period. The decrease at our Spectrum segment was primarily driven by the loss of certain customers and a decrease in direct response advertising, which was partially offset by the launch of new networks subsequent to the comparable period. The increase at our Life Sciences segment was attributable to R2, primarily driven by increases in Glacial Spa unit sales, consumable sales and Glacial fx unit sales outside North America, as well as an increase in Glacial fx unit sales and consumable sales in North America. The increase was partially offset by a decrease in Glacial Rx unit sales in North America.
| REVENUE by OPERATING SEGMENT | |||||||||||||||||||
| (in millions) | Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||
| 2025 | 2024 | Increase / (Decrease) | 2025 | 2024 | Increase / (Decrease) | ||||||||||||||
| Infrastructure | $ | 233.1 | $ | 305.2 | $ | (72.1 | ) | $ | 498.0 | $ | 613.1 | $ | (115.1 | ) | |||||
| Life Sciences | 3.2 | 1.7 | 1.5 | 6.3 | 2.7 | 3.6 | |||||||||||||
| Spectrum | 5.7 | 6.2 | (0.5 | ) | 11.9 | 12.5 | (0.6 | ) | |||||||||||
| Consolidated INNOVATE | $ | 242.0 | $ | 313.1 | $ | (71.1 | ) | $ | 516.2 | $ | 628.3 | $ | (112.1 | ) | |||||
- Net Loss: For the second quarter of 2025, INNOVATE reported a Net loss attributable to common stockholders and participating preferred stockholders of
$22.0 million , or$1.67 per fully diluted share, compared to Net income of$14.1 million , or$1.03 per fully diluted share, for the prior year quarter, which has been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on August 8, 2024. The decrease in Net income was primarily due to a net decrease in gross profit of$20.0 million , a$11.7 million decrease in other operating income, a$6.7 million increase in tax expense, a$4.9 million increase in interest expense, and a$0.5 million decrease in other income, net, which was partially offset by a decrease in selling, and general and administrative (“SG&A”) expenses of$7.8 million , a decrease of$1.1 million in loss from equity investees. The net decrease in gross profit was primarily driven by our Infrastructure segment due to timing and size of projects that have since been completed or are nearing completion in the current period, including the effect of changes in estimated costs to complete those projects recognized in the ordinary course of business in the comparable period. The decrease in other operating income was primarily driven by our Infrastructure segment as a result of unrepeated gains on lease modifications and unrepeated gains on the sale of various properties in the comparable period, as well as various losses on the sale of properties and a loss on lease modification in the current period. The increase in tax expense was primarily driven by the impact of projected pre-tax results on the annual effective tax rate and the limitations on the utilization of net operating losses (“NOL”) by INNOVATE's U.S. consolidated group as a result of the Internal Revenue Code Section 382 and the Tax Cuts and Jobs Act's 80 percent limitation on NOLs incurred after 2017. The increase in interest expense was primarily attributable to increases in exit fees and a higher outstanding principal balance at our Life Sciences segment as a result of the capitalization of unpaid interest into the principal balance subsequent to the comparable period. The decrease in SG&A expenses was primarily driven by our Infrastructure segment as a result of a decrease in compensation-related expenses due to timing. The overall decrease in loss from equity investees was due to Pansend being unable to recognize any losses from MediBeacon as Pansend's net carrying amount of its investment in MediBeacon was zero during the second quarter.
| NET INCOME (LOSS) by OPERATING SEGMENT | ||||||||||||||||||||||||
| (in millions) | Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2025 | 2024 | Increase / (Decrease) | 2025 | 2024 | Increase / (Decrease) | |||||||||||||||||||
| Infrastructure | $ | 5.5 | $ | 21.0 | $ | (15.5 | ) | $ | 10.1 | $ | 25.4 | $ | (15.3 | ) | ||||||||||
| Life Sciences | (6.5 | ) | (3.8 | ) | (2.7 | ) | (14.1 | ) | (8.3 | ) | (5.8 | ) | ||||||||||||
| Spectrum | (6.1 | ) | (5.0 | ) | (1.1 | ) | (11.5 | ) | (9.8 | ) | (1.7 | ) | ||||||||||||
| Non-Operating Corporate | (12.7 | ) | 2.1 | (14.8 | ) | (28.8 | ) | (10.4 | ) | (18.4 | ) | |||||||||||||
| Other and eliminations | — | 0.1 | (0.1 | ) | — | 0.1 | (0.1 | ) | ||||||||||||||||
| Net (loss) income attributable to INNOVATE Corp. | $ | (19.8 | ) | $ | 14.4 | (34.2 | ) | $ | (44.3 | ) | $ | (3.0 | ) | $ | (41.3 | ) | ||||||||
| Less: Preferred dividends | 2.2 | 0.3 | 1.9 | 2.5 | 0.6 | 1.9 | ||||||||||||||||||
| Net (loss) income attributable to common stockholders and participating preferred stockholders | $ | (22.0 | ) | $ | 14.1 | $ | (36.1 | ) | $ | (46.8 | ) | $ | (3.6 | ) | $ | (43.2 | ) | |||||||
- Adjusted EBITDA: For the second quarter of 2025, Total Adjusted EBITDA was
$15.7 million compared to Total Adjusted EBITDA of$26.7 million for the prior year quarter. The decrease in Adjusted EBITDA was primarily driven by our Infrastructure segment and to a lesser extent our Spectrum segment, which was partially offset by an increase at our Life Sciences segment and to a lesser extent our Non-Operating Corporate segment. The decrease at our Infrastructure segment was primarily driven by a decrease in revenue and gross margins at DBMG's commercial structural steel fabrication and erection business, a decrease in revenue at Banker Steel and a decrease in revenue and gross margins at the construction modeling and detailing business, due to timing of certain large commercial construction projects that have since been completed or are nearing completion in the current period. This decrease was partially offset by an improvement in gross margins at the industrial maintenance and repair business, and a decrease in recurring SG&A expenses, primarily driven by a decrease in compensation-related expenses due to timing. The decrease at our Spectrum segment was driven by the decrease in revenue. The increase in Adjusted EBITDA at our Life Sciences segment was primarily driven by a decrease in equity method losses recognized from MediBeacon, as Pansend was unable to recognize any losses from MediBeacon due to Pansend's net carrying amount of its investment in MediBeacon being zero during the second quarter, as well as an increase in gross profit at R2 due to the increase in revenue, and a decrease in SG&A expenses at R2. The increase in Adjusted EBITDA at our Non-Operating Corporate segment driven by a decrease in SG&A expenses primarily due to a decrease in legal fees following legal matters settled subsequent to the comparable period, as well as a slight decrease in employee-related expenses, accounting and other professional expenses and insurance expense.
| ADJUSTED EBITDA by OPERATING SEGMENT | |||||||||||||||||||||||
| (in millions) | Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||
| 2025 | 2024 | Increase / (Decrease) | 2025 | 2024 | Increase / (Decrease) | ||||||||||||||||||
| Infrastructure | $ | 19.3 | $ | 32.5 | $ | (13.2 | ) | $ | 36.0 | $ | 50.8 | $ | (14.8 | ) | |||||||||
| Life Sciences | (2.6 | ) | (4.8 | ) | 2.2 | (11.3 | ) | (9.0 | ) | (2.3 | ) | ||||||||||||
| Spectrum | 1.0 | 1.5 | (0.5 | ) | 2.4 | 3.1 | (0.7 | ) | |||||||||||||||
| Non-Operating Corporate | (2.0 | ) | (2.5 | ) | 0.5 | (4.2 | ) | (5.4 | ) | 1.2 | |||||||||||||
| Other and eliminations | — | — | — | — | — | — | |||||||||||||||||
| Total Adjusted EBITDA | $ | 15.7 | $ | 26.7 | $ | (11.0 | ) | $ | 22.9 | $ | 39.5 | $ | (16.6 | ) | |||||||||
- Balance Sheet: As of June 30, 2025, INNOVATE had cash and cash equivalents, excluding restricted cash, of
$33.4 million compared to$48.8 million as of December 31, 2024. On a stand-alone basis, as of June 30, 2025, our Non-Operating Corporate segment had cash and cash equivalents of$3.1 million compared to$13.8 million as of December 31, 2024.
Conference Call
INNOVATE will host a live conference call to discuss its second quarter 2025 financial results and operations today at 4:30 p.m. ET. The Company will post an earnings supplemental presentation in the Investor Relations section of the INNOVATE website at innovate-ir.com to accompany the conference call. Dial-in instructions for the conference call and the replay follows.
- Live Webcast and Call. A live webcast of the conference call can be accessed by interested parties through the Investor Relations section of the INNOVATE website at innovate-ir.com.
- Dial-in: 1-877-704-4453 (Domestic Toll Free) / 1-201-389-0920 (Toll/International)
- Conference Replay*
- Dial-in: 1-844-512-2921 (Domestic Toll Free) / 1-412-317-6671 (Toll/International)
- Conference Number: 13754924
*Available approximately three hours after the end of the conference call through August 19, 2025.
About INNOVATE
INNOVATE is a portfolio of best-in-class assets in three key areas of the new economy – Infrastructure, Life Sciences and Spectrum. Dedicated to stakeholder capitalism, INNOVATE employs approximately 3,100 people across its subsidiaries. For more information, please visit: www.INNOVATECorp.com.
Contacts
Investor Contact:
Anthony Rozmus
ir@innovatecorp.com
(212) 235-2691
Non-GAAP Financial Measures
In this press release, INNOVATE refers to certain financial measures that are not presented in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), including Total Adjusted EBITDA (excluding discontinued operations, if applicable) and Adjusted EBITDA for its operating segments. In addition, other companies may define Adjusted EBITDA differently than we do, which could limit its usefulness.
Adjusted EBITDA
Management believes that Adjusted EBITDA provides investors with meaningful information for gaining an understanding of our results as it is frequently used by the financial community to provide insight into an organization’s operating trends and facilitates comparisons between peer companies, since interest, taxes, depreciation, amortization and the other items listed in the definition of Adjusted EBITDA below can differ greatly between organizations as a result of differing capital structures and tax strategies. Adjusted EBITDA can also be a useful measure of a company’s ability to service debt. While management believes that non-U.S. GAAP measurements are useful supplemental information, such adjusted results are not intended to replace our U.S. GAAP financial results. Using Adjusted EBITDA as a performance measure has inherent limitations as an analytical tool as compared to net income (loss) or other U.S. GAAP financial measures, as this non-U.S. GAAP measure excludes certain items, including items that are recurring in nature, which may be meaningful to investors. As a result of the exclusions, Adjusted EBITDA should not be considered in isolation and does not purport to be an alternative to net income (loss) or other U.S. GAAP financial measures as a measure of our operating performance.
The calculation of Adjusted EBITDA, as defined by us, consists of Net income (loss) attributable to INNOVATE Corp., excluding: discontinued operations, if applicable; depreciation and amortization; other operating (income) loss, which is inclusive of (gain) loss on sale or disposal of assets, lease termination costs, (gains) losses on lease modifications, and asset impairment expense; interest expense; other (income) expense, net; income tax expense (benefit); non-controlling interest; share-based compensation expense; realignment and exit costs; and acquisition and disposition costs.
Cautionary Statement Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release contains, and certain oral statements made by our representatives from time to time may contain, “forward-looking statements.” Generally, forward-looking statements include information describing actions, events, results, strategies and expectations and are generally identifiable by use of the words “believes,” “expects,” “intends,” “anticipates,” “plans,” “seeks,” “estimates,” “projects,” “may,” “will,” “could,” “might,” or “continues” or similar expressions. Such forward-looking statements are based on current expectations and inherently involve certain risks, assumptions and uncertainties. The forward-looking statements in this press release include, without limitation, any statements regarding INNOVATE’s plans and expectations for future growth and ability to capitalize on potential opportunities, the achievement of INNOVATE’s strategic objectives, negotiation of definitive terms, holder participation, fulfillment or waiver of closing conditions and successful settlement of each of the refinancing transactions described in this press release, expectations for performance of new projects and realization of revenue from the backlog at DBMG and the Infrastructure segment, anticipated success from the continued sale of new products in the Life Sciences segment, necessary regulatory approvals of products and potential applications of the TGFR with clinicians in the Life Sciences segment, potential commercial opportunities in datacasting, the deployment of new technologies and launching of new networks and stations at the Spectrum segment, our ability to remain in compliance with the NYSE's continued listing standards, and changes in macroeconomic and market conditions and market volatility, including interest rates, the value of securities and other financial assets, and the impact of such changes and volatility on INNOVATE’s financial position. Such statements are based on the beliefs and assumptions of INNOVATE’s management and the management of INNOVATE’s subsidiaries and portfolio companies.
The Company believes these judgments are reasonable, but these statements are not guarantees of performance, results or the creation of stockholder value and the Company’s actual results could differ materially from those expressed or implied in the forward-looking statements due to a variety of important factors, both positive and negative, including those that may be identified in subsequent statements and reports filed with the Securities and Exchange Commission (“SEC”), including in our reports on Forms 10-K, 10-Q, and 8-K. Such important factors include, without limitation: our dependence on distributions from our subsidiaries to fund our operations and payments on our obligations; our ability to continue operating as a going concern; the impact on our business and financial condition of our substantial indebtedness and any significant additional indebtedness and other financing obligations we may incur; our possible inability to raise additional capital when needed or refinance our existing debt, on attractive terms, or at all; our dependence on the retaining and recruitment of key personnel; volatility in the trading price of our common stock; the impact of potential supply chain disruptions, labor shortages and increases in overall price levels, including in steel and transportation costs; interest rate environment; developments relating to the ongoing hostilities in Ukraine and Israel; increased competition in the markets in which our operating segments conduct their businesses; our ability to successfully identify any strategic acquisitions or business opportunities; uncertain global economic conditions in the markets in which our operating segments conduct their businesses; changes in regulations and tax laws; covenant noncompliance risk; tax consequences associated with our acquisitions, holding and disposition of target companies and assets; the ability of our operating segments to attract and retain customers; our expectations regarding the timing, extent and effectiveness of any cost reduction initiatives and management’s ability to moderate or control discretionary spending; our expectations and timing with respect to any strategic dispositions and sales of our operating subsidiaries, or businesses; and the possibility of indemnification claims arising out of divestitures of businesses.
Although INNOVATE believes its expectations and assumptions regarding its future operating performance are reasonable, there can be no assurance that the expectations reflected herein will be achieved. These risks and other important factors discussed under the caption “Risk Factors” in our most recent Annual Report on Form 10-K filed with the SEC, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release.
You should not place undue reliance on forward-looking statements. All forward-looking statements attributable to INNOVATE or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. All such statements speak only as of the date made, and unless legally required, INNOVATE undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
| INNOVATE CORP. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in millions, except shares and per share amounts) (Unaudited) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue | $ | 242.0 | $ | 313.1 | $ | 516.2 | $ | 628.3 | ||||||||
| Cost of revenue | 196.4 | 247.5 | 425.1 | 514.1 | ||||||||||||
| Gross profit | 45.6 | 65.6 | 91.1 | 114.2 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling, general and administrative | 35.1 | 42.9 | 72.9 | 82.4 | ||||||||||||
| Depreciation and amortization | 4.4 | 4.4 | 8.8 | 8.8 | ||||||||||||
| Other operating loss (income) | 1.2 | (10.5 | ) | 1.1 | (8.6 | ) | ||||||||||
| Income from operations | 4.9 | 28.8 | 8.3 | 31.6 | ||||||||||||
| Other (expense) income: | ||||||||||||||||
| Interest expense | (21.4 | ) | (16.5 | ) | (41.6 | ) | (33.7 | ) | ||||||||
| Loss from equity investees | — | (1.1 | ) | (5.9 | ) | (2.3 | ) | |||||||||
| Other (expense) income, net | (0.3 | ) | 0.2 | 3.7 | (1.0 | ) | ||||||||||
| (Loss) income from operations before income taxes | (16.8 | ) | 11.4 | (35.5 | ) | (5.4 | ) | |||||||||
| Income tax (expense) benefit | (4.2 | ) | 2.5 | (11.3 | ) | (0.8 | ) | |||||||||
| Net (loss) income | (21.0 | ) | 13.9 | (46.8 | ) | (6.2 | ) | |||||||||
| Net loss attributable to non-controlling interests and redeemable non-controlling interests | 1.2 | 0.5 | 2.5 | 3.2 | ||||||||||||
| Net (loss) income attributable to INNOVATE Corp. | (19.8 | ) | 14.4 | (44.3 | ) | (3.0 | ) | |||||||||
| Less: Preferred dividends | 2.2 | 0.3 | 2.5 | 0.6 | ||||||||||||
| Net (loss) income attributable to common stockholders and participating preferred stockholders | $ | (22.0 | ) | $ | 14.1 | $ | (46.8 | ) | $ | (3.6 | ) | |||||
| (Loss) earnings per common share(1) | ||||||||||||||||
| Basic | $ | (1.67 | ) | $ | 1.11 | $ | (3.56 | ) | $ | (0.35 | ) | |||||
| Diluted | $ | (1.67 | ) | $ | 1.03 | $ | (3.56 | ) | $ | (0.35 | ) | |||||
| Weighted-average common shares outstanding(1) | ||||||||||||||||
| Basic | 13,146,750 | 8,920,485 | 13,130,930 | 8,392,923 | ||||||||||||
| Diluted | 13,146,750 | 14,425,756 | 13,130,930 | 8,392,923 | ||||||||||||
(1) Basic and diluted (loss) earnings per common share and basic and diluted weighted-average common shares outstanding for the three months and six months ended June 30, 2024, have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on August 8, 2024.
| INNOVATE CORP. CONDENSED CONSOLIDATED BALANCE SHEETS (in millions, except share amounts) (Unaudited) | ||||||||
| June 30, 2025 | December 31, 2024 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 33.4 | $ | 48.8 | ||||
| Accounts receivable, net | 242.7 | 194.0 | ||||||
| Contract assets | 83.0 | 106.3 | ||||||
| Inventory | 20.7 | 20.8 | ||||||
| Other current assets | 18.6 | 21.0 | ||||||
| Total current assets | 398.4 | 390.9 | ||||||
| Investments | 4.4 | 3.6 | ||||||
| Deferred tax asset | 1.6 | 1.6 | ||||||
| Property, plant and equipment, net | 132.1 | 133.6 | ||||||
| Goodwill | 126.9 | 126.7 | ||||||
| Intangibles, net | 168.6 | 172.4 | ||||||
| Other assets | 58.9 | 62.3 | ||||||
| Total assets | $ | 890.9 | $ | 891.1 | ||||
| Liabilities, temporary equity and stockholders’ deficit | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 80.2 | $ | 84.8 | ||||
| Accrued liabilities | 125.4 | 109.7 | ||||||
| Current portion of debt obligations | 477.5 | 162.2 | ||||||
| Contract liabilities | 172.8 | 109.1 | ||||||
| Other current liabilities | 17.2 | 17.2 | ||||||
| Total current liabilities | 873.1 | 483.0 | ||||||
| Deferred tax liability | 4.5 | 4.4 | ||||||
| Debt obligations | 160.1 | 500.6 | ||||||
| Other liabilities | 42.5 | 46.8 | ||||||
| Total liabilities | 1,080.2 | 1,034.8 | ||||||
| Commitments and contingencies | ||||||||
| Temporary equity | ||||||||
| Preferred Stock Series A-3 and Preferred Stock Series A-4, | 17.9 | 16.1 | ||||||
| Shares authorized: 20,000,000; Shares issued and outstanding: 6,125 of Series A-3 and 10,000 of Series A-4 | ||||||||
| Redeemable non-controlling interest | (0.8 | ) | (0.5 | ) | ||||
| Total temporary equity | 17.1 | 15.6 | ||||||
| Stockholders’ deficit | ||||||||
| Common stock, | — | — | ||||||
| Shares authorized: 250,000,000 | ||||||||
| Shares issued: 13,499,991 and 13,410,179, respectively | ||||||||
| Shares outstanding: 13,336,149 and 13,261,379, respectively | ||||||||
| Additional paid-in capital | 349.2 | 350.1 | ||||||
| Treasury stock, at cost: 163,842 and 148,800 shares, respectively | (5.6 | ) | (5.4 | ) | ||||
| Accumulated deficit | (566.2 | ) | (521.9 | ) | ||||
| Accumulated other comprehensive loss | (2.2 | ) | (3.2 | ) | ||||
| Total INNOVATE Corp. stockholders’ deficit | (224.8 | ) | (180.4 | ) | ||||
| Non-controlling interest | 18.4 | 21.1 | ||||||
| Total stockholders’ deficit | (206.4 | ) | (159.3 | ) | ||||
| Total liabilities, temporary equity and stockholders’ deficit | $ | 890.9 | $ | 891.1 | ||||
| INNOVATE CORP. RECONCILIATION OF NET INCOME (LOSS) TO ADJUSTED EBITDA (Unaudited, in millions) | ||||||||||||||||||||||||
| (in millions) | Three Months Ended June 30, 2025 | |||||||||||||||||||||||
| Infrastructure | Life Sciences | Spectrum | Non- Operating Corporate | Other and Eliminations | INNOVATE | |||||||||||||||||||
| Net income (loss) attributable to INNOVATE Corp. | $ | 5.5 | $ | (6.5 | ) | $ | (6.1 | ) | $ | (12.7 | ) | $ | — | $ | (19.8 | ) | ||||||||
| Adjustments to reconcile net income (loss) to Adjusted EBITDA: | ||||||||||||||||||||||||
| Depreciation and amortization | 3.1 | 0.1 | 1.2 | — | — | 4.4 | ||||||||||||||||||
| Depreciation and amortization (included in cost of revenue) | 3.0 | — | — | — | — | 3.0 | ||||||||||||||||||
| Other operating loss | 1.2 | — | — | — | — | 1.2 | ||||||||||||||||||
| Interest expense | 2.4 | 5.2 | 3.9 | 9.9 | — | 21.4 | ||||||||||||||||||
| Other expense (income), net | — | — | 2.3 | (2.0 | ) | — | 0.3 | |||||||||||||||||
| Income tax expense | 2.1 | — | — | 2.1 | — | 4.2 | ||||||||||||||||||
| Non-controlling interest | 0.6 | (1.4 | ) | (0.4 | ) | — | — | (1.2 | ) | |||||||||||||||
| Share-based compensation expense | — | — | — | 0.7 | — | 0.7 | ||||||||||||||||||
| Realignment and exit costs | 1.4 | — | 0.1 | — | — | 1.5 | ||||||||||||||||||
| Adjusted EBITDA | $ | 19.3 | $ | (2.6 | ) | $ | 1.0 | $ | (2.0 | ) | $ | — | $ | 15.7 | ||||||||||
| (in millions) | Three Months Ended June 30, 2024 | |||||||||||||||||||||||
| Infrastructure | Life Sciences | Spectrum | Non- Operating Corporate | Other and Eliminations | INNOVATE | |||||||||||||||||||
| Net income (loss) attributable to INNOVATE Corp. | $ | 21.0 | $ | (3.8 | ) | $ | (5.0 | ) | $ | 2.1 | $ | 0.1 | $ | 14.4 | ||||||||||
| Adjustments to reconcile net income (loss) to Adjusted EBITDA: | ||||||||||||||||||||||||
| Depreciation and amortization | 2.9 | 0.1 | 1.3 | 0.1 | — | 4.4 | ||||||||||||||||||
| Depreciation and amortization (included in cost of revenue) | 3.8 | 0.1 | — | — | — | 3.9 | ||||||||||||||||||
| Other operating (income) loss | (10.5 | ) | — | 0.1 | (0.1 | ) | — | (10.5 | ) | |||||||||||||||
| Interest expense | 2.0 | 1.0 | 3.4 | 10.1 | — | 16.5 | ||||||||||||||||||
| Other (income) expense, net | (0.3 | ) | (0.3 | ) | 2.1 | (1.6 | ) | (0.1 | ) | (0.2 | ) | |||||||||||||
| Income tax expense (benefit) | 10.9 | — | — | (13.4 | ) | — | (2.5 | ) | ||||||||||||||||
| Non-controlling interest | 2.0 | (2.0 | ) | (0.5 | ) | — | — | (0.5 | ) | |||||||||||||||
| Share-based compensation expense | — | 0.1 | — | 0.3 | — | 0.4 | ||||||||||||||||||
| Realignment and exit costs | 0.7 | — | — | — | — | 0.7 | ||||||||||||||||||
| Acquisition and disposition costs | — | — | 0.1 | — | — | 0.1 | ||||||||||||||||||
| Adjusted EBITDA | $ | 32.5 | $ | (4.8 | ) | $ | 1.5 | $ | (2.5 | ) | $ | — | $ | 26.7 | ||||||||||
| (in millions) | Six Months Ended June 30, 2025 | |||||||||||||||||||||||
| Infrastructure | Life Sciences | Spectrum | Non- Operating Corporate | Other and Eliminations | INNOVATE | |||||||||||||||||||
| Net income (loss) attributable to INNOVATE Corp. | $ | 10.1 | $ | (14.1 | ) | $ | (11.5 | ) | $ | (28.8 | ) | $ | — | $ | (44.3 | ) | ||||||||
| Adjustments to reconcile net income (loss) to Adjusted EBITDA: | ||||||||||||||||||||||||
| Depreciation and amortization | 6.2 | 0.2 | 2.4 | — | — | 8.8 | ||||||||||||||||||
| Depreciation and amortization (included in cost of revenue) | 6.5 | — | — | — | — | 6.5 | ||||||||||||||||||
| Other operating loss | 1.1 | — | — | — | — | 1.1 | ||||||||||||||||||
| Interest expense | 4.5 | 9.7 | 7.6 | 19.8 | — | 41.6 | ||||||||||||||||||
| Other (income) expense, net | (0.3 | ) | (4.5 | ) | 4.5 | (3.4 | ) | — | (3.7 | ) | ||||||||||||||
| Income tax expense | 4.4 | — | — | 6.9 | — | 11.3 | ||||||||||||||||||
| Non-controlling interest | 1.0 | (2.8 | ) | (0.7 | ) | — | — | (2.5 | ) | |||||||||||||||
| Share-based compensation expense | — | 0.2 | — | 1.3 | — | 1.5 | ||||||||||||||||||
| Realignment and exit costs | 2.5 | — | 0.1 | — | — | 2.6 | ||||||||||||||||||
| Adjusted EBITDA | $ | 36.0 | $ | (11.3 | ) | $ | 2.4 | $ | (4.2 | ) | $ | — | $ | 22.9 | ||||||||||
| INNOVATE CORP. RECONCILIATION OF NET INCOME (LOSS) TO ADJUSTED EBITDA (Unaudited, in millions) | ||||||||||||||||||||||||
| (in millions) | Six Months Ended June 30, 2024 | |||||||||||||||||||||||
| Infrastructure | Life Sciences | Spectrum | Non- Operating Corporate | Other and Eliminations | INNOVATE | |||||||||||||||||||
| Net income (loss) attributable to INNOVATE Corp. | $ | 25.4 | $ | (8.3 | ) | $ | (9.8 | ) | $ | (10.4 | ) | $ | 0.1 | $ | (3.0 | ) | ||||||||
| Adjustments to reconcile net income (loss) to Adjusted EBITDA: | ||||||||||||||||||||||||
| Depreciation and amortization | 5.9 | 0.2 | 2.6 | 0.1 | — | 8.8 | ||||||||||||||||||
| Depreciation and amortization (included in cost of revenue) | 7.8 | 0.1 | — | — | — | 7.9 | ||||||||||||||||||
| Other operating (income) loss | (8.9 | ) | — | 0.1 | 0.2 | — | (8.6 | ) | ||||||||||||||||
| Interest expense | 4.7 | 1.9 | 6.8 | 20.3 | — | 33.7 | ||||||||||||||||||
| Other (income) expense, net | (1.1 | ) | 1.7 | 4.1 | (3.6 | ) | (0.1 | ) | 1.0 | |||||||||||||||
| Income tax expense (benefit) | 13.4 | — | — | (12.6 | ) | — | 0.8 | |||||||||||||||||
| Non-controlling interest | 2.4 | (4.8 | ) | (0.8 | ) | — | — | (3.2 | ) | |||||||||||||||
| Share-based compensation expense | — | 0.2 | — | 0.6 | — | 0.8 | ||||||||||||||||||
| Realignment and exit costs | 1.2 | — | — | — | — | 1.2 | ||||||||||||||||||
| Acquisition and disposition costs | — | — | 0.1 | — | — | 0.1 | ||||||||||||||||||
| Adjusted EBITDA | $ | 50.8 | $ | (9.0 | ) | $ | 3.1 | $ | (5.4 | ) | $ | — | $ | 39.5 | ||||||||||
FAQ
What were INNOVATE Corp's (VATE) key financial results for Q2 2025?
How much backlog does INNOVATE's Infrastructure segment (DBMG) have in Q2 2025?
What was the performance of INNOVATE's Life Sciences segment in Q2 2025?
What refinancing transactions did INNOVATE complete in 2025?
How did INNOVATE's Spectrum segment perform in Q2 2025?
